Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07474467RecruitingPhase 1/Phase 2
Stem cell therapy for acne scars
This trial tests a treatment made from your own fat cells to improve deep acne scars. It aims to see if the therapy is safe and helps reduce the appearance of scars.
SeoulAges 19 years+ - NCT06780826Recruiting
Atezolizumab plus chemo for extensive-stage small cell lung cancer
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
ShanghaiAges 18 years+ - NCT07479927Recruiting
Online brain training and mindfulness for kids after leukemia treatment
This study tests if a computer-based training program focusing on thinking skills and mindfulness can help children and teens who have had leukemia treatment. It may help improve memory, attention, and emotional well-being.
Madrid, MadridAges 8–18 - NCT07477158Recruiting
Comparing two lung cancer surgeries for recovery and quality of life
This study compares two types of lung cancer surgery—removing just the tumor section (segmentectomy) or the whole lobe (lobectomy)—done through small cuts (minimally invasive). The goal is to see which approach leads to better daily living and recovery for early-stage lung cancer patients.
Madrid, MadridAges 18 years+ - NCT07479277Recruiting
Progel to reduce air leaks after lung surgery
This trial tests whether a special gel (Progel Platinum) can reduce air leaks that sometimes happen after lung cancer surgery. It is for people having minimally invasive surgery to remove the upper or lower lobe of the lung.
Candiolo, TorinoAges 18–99 - NCT07478809Recruiting
Long-term study of RATIONALE-307 trial participants
This study looks back at people who took part in the RATIONALE-307 trial for a type of lung cancer called squamous non-small cell lung cancer. It aims to learn more about their health outcomes over time by only including those who were still alive when the original trial ended.
BeijingAges Any age - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT06783270RecruitingPhase 1
T-Cell Therapy for Advanced Melanoma
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Herlev, Capital RegionAges 18–75 - NCT06784440Recruiting
Finding noninvasive markers of graft injury after heart transplant
This study looks for noninvasive markers (like blood or urine tests) that can show if a heart transplant is being injured. It aims to make monitoring safer and easier for children and adults with congenital heart disease who have had a transplant.
BolognaAges Up to 44 years - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT04807881RecruitingPhase 1
Study of keynatinib for certain hard-to-treat lymphomas
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT06788470RecruitingPhase 1/Phase 2
Stem cell therapy for severe lung disease in premature babies
This trial tests whether umbilical cord stem cells can help premature babies with severe bronchopulmonary dysplasia (a chronic lung disease) who still need a breathing tube after standard hormone treatment. The goal is to see if it is safe and improves their lung condition.
Hangzhou, ZhejiangAges 8 months+ - NCT06293950RecruitingPhase 1
Stem cell therapy for children with autism
This trial tests whether stem cells from donated umbilical cord tissue can help children with autism. It is for children aged 4–14 who weigh at least 10 kg and are otherwise healthy.
AmmanAges 4–14 - NCT05997602RecruitingPhase 2
Testing FCN-159 for children with LCH that returned
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Beijing, Beijing MunicipalityAges 2–16 - NCT07467772RecruitingPhase 2
Elacestrant for estrogen receptor-positive uterine sarcoma
This trial tests whether elacestrant, a drug that blocks estrogen, can help people with certain types of uterine sarcoma that have strong estrogen receptors. It may slow or stop cancer growth in tumors that rely on estrogen.
Boston, MassachusettsAges 18 years+ - NCT07468201Recruiting
New way to collect cord blood stem cells
This study is developing a better way to collect stem cells from donated umbilical cord blood. If you are a healthy pregnant woman, donating your baby's cord blood could help improve treatments for diseases.
Pavia, LombardyAges Any age - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+ - NCT06793813RecruitingPhase 2
Study of cadonilimab for advanced lung cancer
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Scottsdale, ArizonaAges 18 years+ - NCT07459634RecruitingPhase 2
Combination treatment for extensive-stage small cell lung cancer
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
Los Angeles, CaliforniaAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.